Patents by Inventor David J Livingston

David J Livingston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolation of an M.sub.r 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
    Patent number: 5763590
    Abstract: An FK506 binding protein of mammalian origin of approximate size (M.sub.r) 52,000, isolated by FK506 affinity chromatography and a corresponding human cDNA of approximate size 2.2 Kb, isolated by screening a human placenta cDNA library with a DNA probe whose sequence predicts a consensus amino acid sequence present in five FKBP12 sequences and in the human FKBP13 sequence.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: June 9, 1998
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Debra A. Peattie, Matthew W. Harding, David J. Livingston
  • Inhibitors of interleukin-1.beta. converting enzyme
    Patent number: 5716929
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 10, 1998
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Guy W. Bemis, Julian M. C. Golec, David J. Lauffer, Michael D. Mullican, Mark A. Murcko, David J. Livingston
  • Inhibitors of interleukin-1.beta. converting enzyme
    Patent number: 5656627
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
    Type: Grant
    Filed: March 17, 1995
    Date of Patent: August 12, 1997
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Guy W. Bemis, Julian M. C. Golec, David J. Lauffer, Michael D. Mullican, Mark A. Murcko, David J. Livingston